Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Seres Therapeutics, Inc.MCRB · Entity 7191 | See Remarks | August 15, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Seres Therapeutics, Inc.
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,679 |
Ending reported balance
After 2026-08-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-15 · Exercise / conversion · Acquired 181 · Balance 8,743 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Row 2 · 2026-08-17 · Sale · Disposed 64 · Balance 8,679 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 26, 2025, with the intent to cover taxes in connection with the vesting of the restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 179 |
Reported balance
After 2026-08-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-15 · Exercise / conversion · Disposed 90 · Balance 179 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 548 |
Reported balance
After 2026-08-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-15 · Exercise / conversion · Disposed 91 · Balance 548 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 26, 2025, with the intent to cover taxes in connection with the vesting of the restricted stock units.
F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 18, 2026 21:33 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 64 | $4.55 | $291.20 |
DisclosureSEC source: 0001193125-26-355734 · ownership.xml · nonDerivative · entry 2 Brady Kelly · CIK 0002117686 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,679 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 26, 2025, with the intent to cover taxes in connection with the vesting of the restricted stock units. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:33 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 91 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-355734 · ownership.xml · derivative · entry 4 Brady Kelly · CIK 0002117686 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 548 Underlying: Common Stock · 91 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:33 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 90 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-355734 · ownership.xml · derivative · entry 3 Brady Kelly · CIK 0002117686 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 179 Underlying: Common Stock · 90 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:33 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 181 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-355734 · ownership.xml · nonDerivative · entry 1 Brady Kelly · CIK 0002117686 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 20:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001193125-26-300914 · ownership.xml · derivative · entry 1 Brady Kelly · CIK 0002117686 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2036-03-03 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| May 18, 2026 Filed May 19, 2026 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 59 | $7.53 | $444.27 |
DisclosureSEC source: 0001193125-26-230732 · ownership.xml · nonDerivative · entry 2 Brady Kelly · CIK 0002117686 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,562 F2 · kind: Represents shares sold to cover taxes in connection with the vesting of the restricted stock units. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 91 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-230732 · ownership.xml · derivative · entry 4 Brady Kelly · CIK 0002117686 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 639 Underlying: Common Stock · 91 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 89 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-230732 · ownership.xml · derivative · entry 3 Brady Kelly · CIK 0002117686 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269 Underlying: Common Stock · 89 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 180 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-230732 · ownership.xml · nonDerivative · entry 1 Brady Kelly · CIK 0002117686 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| March 04, 2026 Filed Mar 11, 2026 22:39 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 56,250 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001193125-26-102617 · ownership.xml · derivative · entry 1 Brady Kelly · CIK 0002117686 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 56,250 shares Expires 2036-03-03 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.